Many experts in the Life Sciences & Health field will contribute to the Global Impact in Health Symposium. On this page we have put down short bio’s on the contributing experts (not all of them) to give you a valuable insight into what to expect on May 30th! Check out the bio’s here and sign up for the event!
Ida Haisma is currently the director of the Leiden Bio Science Park. In her previous role, Haisma was responsible for digital solutions for Aliander and for numerous start-ups to accelerate the transition to renewable energies.
Prior to this role, Ida was deputy director of the Vereniging Innovatieve Geneesmiddelen (VIG). She was also director of the national safety sector The Hague Security Delta and active at TNO as director of Innovation Safety & Security Research within the theme of Integral Safety.
She has taught at several universities and higher vocational colleges and has also worked as a policy employee International Collaboration at the Ministry of Foreign Affairs. Haisma has positions at Clingendael, Kennis Centrum Grote Stedenbeleid and Centrum voor Criminaliteitspreventie en Veiligheid (CCV). She is very experienced in designing and developing ecosystems with public, private and knowledge and research organizations.
Prof. Pancras Hogendoorn is Professor of Pathology at Leiden University, the Netherlands, and serves as
Vice Chair and Dean of the Executive Board of the Leiden University Medical Center (LUMC) in Leiden, the Netherlands.
He completed his Medical and PhD studies at Leiden University followed by his residency in anatomic pathology. He completed fellowships in oncological pathology at the Dutch Cancer Institute, Amsterdam and Memorial Sloan Kettering Cancer Center, New York.
He holds a chair as visiting professor at the University of Oxford and the University of Brussel and serves as chairman of the Biomed group of the League of European Research Universities (LERU) and is Chief Scientific Officer of the top sector Life Science and Health.
He is elected member of the Academia Europaea and the Royal Academy of Sciences.
Prof. Francisca Oladipo is the executive coordinator of the Africa and Asia Implementation Networks of the Virus Outbreak Data Network Africa, (VODAN Africa & Asia), VODANA. She is a Professor of Computer Science and Director Quality Assurance at Federal University Lokoja Nigeria. She also doubles as the institutions Chair of Computer Science.
VODANA has given Africa a place in the fight against the COVID-19 pandemic by implementing Data-in-Residence in the context of COVID-19 through the deployment of 10 machine-actionable COVID-19 FAIR Data Points across several African countries and the Netherlands. She is currently leading the expansion of the initiative in other countries; and the deployment of digital health data management in 88 health facilities across these countries.
She has won many grants and co-authored several award-winning proposals for donor-founded projects including the Philips Foundation Grants, Google Rapid COVID-19 Grant, Dutch Ministry of Foreign Affairs Orange Knowledge Program, Carnegie African Diaspora Fellowship, Dutch Development Bank Grant for capacity Strengthening in Africa, etc.
Dr. Lieve Fransen is a senior social and health policy advisor with a range of different institutions, businesses and think thanks. She is medical doctor specialized in global public health and social policies worldwide. She has a PhD in social policies at the university of Antwerp, Belgium.
Dr. Fransen has considerable and recognized experience in development and sustainability policies in European and global institutions. She worked extensively on formulating evidence-based policies on social investment and innovation, pensions, education, health and healthcare and gender, HIV and population.
She worked as a medical doctor and in international public health in Africa, Asia, Latin America and Europe. She was also Public Health Advisor to the Ministry of Health in Mozambique, Kenya, Rwanda, Senegal, India and the Cape Verde Islands and has created several new initiatives such as the Global Fund for aids, malaria and TB and was a founding Board member and the vice chair of the Board of the same organization. She was also the director for Social Policy and the European strategy for 2020 and the European semester in the European Commission until May 2015.
Dr. Fransen has received a wide range of awards and recognitions for her lifetime work, is member of several boards worldwide and has many academic and policy publications.
Professor Maria Yazdanbakhsh is head of Parasitology and board member of Leiden University Center of Infectious Diseases. She heads a group that engages in basic and clinical research and consists of an interdisciplinary team of basic and clinical scientists who focus on understanding host-parasite interactions at the molecular, cellular and population level. The knowledge gained is being applied to contribute to 1) development of effective vaccines and 2) identification of parasite-derived immune modulatory molecules to control hyper-inflammatory diseases.
Her work is characterized by both fundamental research in the Leiden laboratories, clinical studies as well as field research in African and Asian countries. In addition to her scientific contribution, she has also ensured that the research capacity of groups of researchers in Indonesia, Gabon and various African countries such as Ghana, Senegal and Uganda has been strengthened. She also plays a crucial role in maintaining long-term collaborations with scientists in these countries, where she is also a visiting professor.
Prof. Meta Roestenberg is an infectious diseases clinician heading the Controlled Human Infection Center at Leiden University Medical Center. She studied Medicine at the University of Maastricht, where she obtained her medical degree cum laude in 2004 and developed a human model for malaria immunity during her PhD at the department of Medical Microbiology of the Radboud University Medical Center, which she completed cum laude in 2013.
She was trained in internal medicine at the Radboud University Medical Center and the Canisius Wilhelmina Hospital, both in Nijmegen and completed training for infectious diseases at the Leiden University Medical Center in 2014. At the Controlled Human Infection Center, she leads a group of translational multidisciplinary scientists, investigating natural- and vaccine-induced immunity in human models for a number of infectious diseases. In addition, she keeps putting efforts into the development of vaccines for important parasitic diseases: malaria and schistosomiasis.
In the future, Meta will continue to focus on clinical translational vaccine research to fight infectious diseases that cause significant morbidity and mortality among the poorest people in the world.
Prof. Mirjam van Reisen is Professor of FAIR Data Science at the Leiden University Medical Center (LUMC) at Leiden University and Professor International Relations, Innovation and Care at Tilburg University. Van Reisen is research leader of the Globalization, Accessibility, Innovation and Care (GAIC) network.
Furthermore, Van Reisen is the coordinator of the Virus Outbreak Data Network (VODAN) Africa implementation network. She is also the director of the organization Research Advisors & Experts Europe (RAEE) in Brussels.
Van Reisen was a member of the Dutch Advisory Council on International Affairs (AIV) and chair of the Development Assistance Committee (COS) from 2013 to 2020 and a member of the board of Philips Foundation and the SNV Netherlands Development Organisation until 2020.
Prof. Mirjam van Reisen has published extensively on Europe and international cooperation, human rights and human trafficking. She leads research into international human trafficking, international cooperation, the role of technology and big data and the position of women in peace building.
Hans Schikan brings over 25 years of experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases. After the acquisition of Prosensa in 2015, he currently serves on the board of several biopharma companies across Europe.
He is also member of the top team of the Dutch Top Sector for Life Sciences and Health, with a focus on mission driven innovation via public-private partnerships. Furthermore, he is involved with two venture capital firms and is actively involved in supporting start-up and scale-up biotech companies. He is co-founder of NASDAQ listed Pharvaris.
Finally, he was Special Envoy for vaccines, appointed by the Dutch Ministry of Health, to explore optimization in the production and scale-up of vaccines for COVID-19.
Prof. Emile Bienvenu holds a B. Pharm, a Master’s degree (Pharmacology) from University of the Western Cape in South Africa, and a PhD (Medical Science) from the University of Gothenburg in Sweden in the area of Clinical Pharmacology.
Prof. Emile Bienvenu has been the Director General of Rwanda FDA since August 2021. Associate Professor of Pharmacology, he previously worked at University of Rwanda (1998 – 2021), where he served as Acting Deputy Vice Chancellor for Academic Affairs and Research (2020-2021), University Director for Innovation (2017-2020), and Executive Secretary for the University Research Office for six years (2002 to 2008). He also served as External Examiner at Muhimbili University of Health & Allied Sciences in Tanzania until 2016. From July 2011 until May 2013 he was the Head of Medical Procurement Division at Rwanda Biomedical Center. Dr. Emile served as the Chairman of the Board of Directors of Rwanda Standards Board (RSB) for 11 years (2009 – 2020) and served as a Member of the Board of Directors at Rwanda Military Hospital (2012-2018).
Hans Hofstraat is Vice President and Senior Fellow & Program Manager at Philips’ Chief Technology Office (CTO). He works with teams in Philips Research, and with colleagues in CTO, Business and Markets across the globe, on innovations in clinical domains such as Cardiovascular Diseases, Oncology and Neurology, and towards universal and equitable Access to Care. He aims to combine clinical insights and context with the opportunities offered by digital healthcare. Together with partners within and beyond Philips, Hans is passionate about identifying major needs in the health-technology domain and to address these by developing meaningful solutions underpinned by proven outcomes. His aim is always to achieve innovations that broaden access to appropriate care and improve quality of life for patients and healthcare professionals.
He is on steering committees of several public-private partnerships, including with the Leiden University Medical Center in the Netherlands and has also worked as (part-time) Professor at the Institute of Molecular Chemistry of the University of Amsterdam, and at the Public Works Department of the Dutch Ministry of Transport and Public Works in The Hague.
Eline founded the TUDelft spin-off and MedTech scale-up NightBalance in 2009 with a new therapy for sleep apnea. NightBalance was acquired by Philips in 2018. Currently, she is the CEO of Hybridize Therapeutics, a spin-off from the LUMC that develops RNA-based therapies for kidney diseases.
Furthermore, she is a Venture Partner at Thuja Capital, is part of the Investment Committee of the Deep Tech Fund of EZ&InvestNL, holds a position in the Investment Committee of the Graduate Entrepreneur Pre Seed Fund and is a member of the Supervisory Board of Livassured (a company that introduces a smart wearable that warns caretakers on epileptic seizures).
Anne Kerber serves as senior vice president, head of Cell Therapy Development at BMS and leads clinical trial and development activities of our cell therapy portfolio. Anne is an experienced leader and drug developer, with particular expertise in cell therapies.
Anne received her M.D. from Philipps University in Marburg, Germany, and completed her clinical training in Internal Medicine at Johann Wolfgang Goethe University Hospital in Frankfurt. She is Board Certified in Internal Medicine and in Hematology/Oncology, and also holds a degree in Pharmaceutical Medicine from the University of Basel, Switzerland.
Professor Annetje Ottow serves as President of Leiden University’s Executive Board. She is responsible for strategy, knowledge transfer, alliances and external relations, international relations, communication, alumni policy, a safe environment, diversity and inclusion, and sustainability at the university. She is also the point of contact for the campus and for campus development in Leiden city centre. She is also Professor of Public Economic Law at Leiden Law School.
Annetje Ottow studied at Leiden University, receiving a Master of Laws (cum laude) in business law, and went on to receive a Master of Laws from Queen Mary College in London. She worked as a private lawyer first at De Brauw Blackston Westbroek and later at Houthoff Buruma, where she was a partner. Ottow was a member of the Board of the Netherlands Independent Post and Telecommunications Authority (OPTA) and non-executive board member of CMA, the Competition and Markets Authority of the United Kingdom.
Ottow obtained her PhD from the University of Amsterdam in June 2006. She specializes in market regulation and supervision, and became Professor of Public Economic Law at Utrecht University in 2007. Ottow served as Dean of the Faculty of Law, Economics and Governance at Utrecht University and was Vice President of the Executive Board of Utrecht University.
Marian Knight is Professor of Maternal and Child Population Health at the National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, UK. She is a public health physician and applied health researcher whose research focuses on the care and prevention of severe complications of pregnancy and early life and addressing disparities in outcomes for women and babies from different population groups. She leads the MBRRACE-UK national Confidential Enquiries into Maternal Deaths and Morbidity and established and was inaugural chair of the International Network of Obstetric Survey Systems (INOSS) to conduct international collaborative and comparative national studies of severe morbidities in pregnancy. In 2021 she received an International Federation of Gynecology and Obstetrics Recognition Award to honour highly distinguished people outside the obstetrics and gynaecology profession who have performed an exceptional service to women’s health.
Bart van Zijll Langhout, PhD – Chairman Leiden Bio Science Park Foundation
Since January 2020 Bart is Chairman of the Leiden Bio Science Park Foundation.
From October 1988 till December 2021 Bart worked for Johnson & Johnson in senior roles at local, regional and global level. His career includes roles in Sales & Marketing and Strategic Alliances as well as Managing Director roles for Switzerland, Benelux, Crucell and Janssen Mid-Sized Markets. In his last function with Johnson & Johnson, Bart led the Janssen Campus The Netherlands and the Janssen EMEA Corona Vaccine Alliance Team.
Bart holds a PhD in developmental genetics from the State University of Leiden.